What is the role of intravenous immunoglobulin (IVIG) in the treatment of acute GVHD following allogeneic BMT?

Updated: Jul 05, 2018
  • Author: Jessica Katz, MD, PhD, FACP; Chief Editor: Emmanuel C Besa, MD  more...
  • Print


IVIG has been shown to decrease the severity of acute graft versus host disease in recipients of allogeneic bone marrow transplants. The dosage is 250 or 500 mg/kg/wk. Prevention against acute graft versus host disease with IVIG might be mediated by the induction of apoptosis of activated alloreactive CD4+ CD134+ donor T cells. [37]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!